CAPVIDIA

Their core work

CAPVIDIA is a Belgian software SME specializing in simulation verification and validation (V&V) technology — the discipline of confirming that digital models accurately predict real-world behavior. They build tools that sit at the intersection of engineering simulation and digital quality assurance, making them valuable wherever computational models must be trusted before physical prototypes or clinical tests are run. In the BOOST 4.0 project, they contributed digital capabilities to Big Data-driven smart manufacturing environments. In SimInSitu, they apply their in-silico V&V expertise to developing virtual testing platforms for heart valves, enabling computational clinical trials as an alternative to costly physical ones.

What they specialise in

How they've shifted over time

In their first H2020 project (2018–2020), CAPVIDIA worked in a pure manufacturing and Industry 4.0 context — Big Data pipelines for connected smart factories — with no apparent life-science dimension. By their second project (2021–2025), the focus had shifted entirely toward biomedical simulation: heart valves, endogenous tissue restoration, and in-silico clinical trials. The common thread across both phases is simulation and digital validation software, suggesting CAPVIDIA is deliberately expanding its V&V platform from industrial applications into the regulated medical device space.

CAPVIDIA is moving from industrial digital tools toward high-value regulated markets — specifically in-silico clinical trials for medical devices — which points to future collaboration opportunities in digital health, MedTech, and computational medicine.

How they like to work

CAPVIDIA has participated exclusively as a consortium partner, never as project coordinator, across both H2020 projects. They work in large, multi-national consortia — 65 unique partners across just two projects — which suggests they are sought as a specialist contributor bringing a defined technical capability rather than acting as an integrator or project driver. This profile makes them a reliable, low-overhead partner for consortia that need credible simulation or V&V expertise without the complexity of managing a technology SME in a lead role.

CAPVIDIA has built connections with 65 unique consortium partners across 17 countries through just two projects, indicating they are embedded in broad, active European research networks rather than narrow bilateral collaborations. Their reach is genuinely pan-European, spanning both industrial and biomedical research ecosystems.

What sets them apart

CAPVIDIA occupies an unusual position as a software SME whose simulation V&V tools are domain-agnostic enough to apply in both advanced manufacturing and clinical medical device development — two sectors that rarely share the same partner. This cross-domain portability, combined with their in-silico clinical trial experience under SimInSitu, makes them particularly valuable for MedTech consortia that need a partner familiar with regulatory-grade computational validation. For consortia in manufacturing or digital health, they bring a focused technical product rather than broad consulting.

Highlights from their portfolio

• SimInSitu
  With EUR 920,625 in EC funding and a focus on virtual clinical trials for tissue-engineered heart valves, this is CAPVIDIA's largest and most scientifically ambitious project, positioning them at the frontier of in-silico regulatory science for implantable medical devices.
• BOOST 4.0
  This project established CAPVIDIA's H2020 track record in Industry 4.0 and Big Data, connecting them to the European smart manufacturing ecosystem that remains a potential channel for their digital tools.